208 search results
21DRA034: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Location: Lebanon
22BRO713 : Clinical feasibility of (ATAC-array + HNF1b IHC) as a diagnostic test to predict the first-line chemotherapy response in pancreatic cancer
Location: Lebanon
22FIN437 - LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable EaRly Stage Lung Cancer
Location: Lebanon
22LAN616: (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF
THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS
WITH NONADVANCED SYSTEMIC MASTOCYTOSIS
Location: Lebanon
22LAN712: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Grade 1-3a when
Administered in the Outpatient Setting
Location: Lebanon
22MIL441: CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth (CATRINA)
Location: Lebanon
23CAS955: A randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-high recurrent platinum-sensitive epithelial ovarian, fallopi
Location: Lebanon
23CUR057: Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined with Selected Standard of Care Therapies for Prostate Cancer
Location: Lebanon
23SHI918: A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer
Location: Lebanon
23YER913: A phase II multicenter, open-label, single-arm, dose escalation study of Asciminib monotherapy in 2nd line chronic phase- chronic Myelogenous Leukemia (ASC2ESCALATE)
Location: Lebanon
24SAN295 - Expanded Access for the Use of Mifamurtide Intravenous Infusion in a Single Patient with Non-metatstatic Osteosarcoma
Location: Lebanon
A Pilot Trial Examining Patient Education Regarding Emotional Stressors on Patient Reported Outcomes in patients undergoing Cellular Therapy
Location: Lebanon
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Location: Lebanon, St. Johnsbury, VT
A051902: A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas
Location: Lebanon
ACNS1831 - A Phase 3 Randomized Study of Selumetinib (IND# 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Location: Lebanon
ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofi
Location: Lebanon
AGCT1532 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Location: Lebanon
ANHL1931: A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Location: Lebanon
Assessing the Predictive Potential of Early Chimerism Analysis Following Allogeneic Stem-Cell Transplant
Location: Lebanon
CliNIcal Utility of ManaGement of Patients witH CT and LDCT Identified
Pulmonary Nodules UsinG the Percepta NasAL Swab ClassifiEr
(NIGHTINGALE) -with Familiarization
Location: Lebanon
Co-developing and pilot testing a risk-tailored, technology-supported intervention to increase home radon testing in New Hampshire and Vermont
Location: Lebanon
D20020 - Manage Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commer
Location: Lebanon
D21008: CORE: CO monitoring for Reach and Efficacy in Tobacco Treatment for Cancer Patients
Location: Lebanon
Developing and testing an online pathway from screening to treatment for depression in oncology: iPath*D
Location: Lebanon
Developing and testing an online pathway from screening to treatment for depression in oncology: iPath*D (Aim 2)
Location: Lebanon
Development of an Early Neurotoxicity Assessment Tool to Optimize
Management after CAR T Cell Therapy - A Pilot Study
Location: Lebanon
EA8212 : A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Location: Lebanon
EA9152: A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine or Vincristine Sulfate in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Location: Lebanon
Effect of Hyperbaric Oxygen Therapy on Urine Inflammatory Biomarkers in Chronic Radiation Cystitis
Location: Lebanon
F18171: M16-185 A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects with Hematologic Malignancies
Location: Lebanon
Immune profiling for cancer immunotherapy response
Location: Lebanon, St. Johnsbury, VT
Implementing Shared Decision Making for Breast Cancer Using a Coproduction Learning Collaborative
Location: Lebanon
Inclusive patient education materials and medical provider/staff training to improve cervical and breast cancer screening among patients who have or have had obesity
Location: Lebanon
Inositol phospholipid-modifying enzymes in predicting T cell infiltration and therapeutic response in breast cancer
Location: Lebanon
Low level VAF MYD88 calling by next-generation sequencing
Location: Lebanon
NOBLE: NOse Brushings for Lung Cancer Assessment in EpitheliumAn Evaluation of a Biomarker Test(s) as an Early Aid in the Risk Assessment of Lung Nodules Detected by Low-Dose CT During Lung Cancer Screening or Incidentally Detected Lung Nodules
Location: Lebanon
NRG-HN010 : A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
Location: Lebanon
Neuropsychological Assessment System for Cancer Patients
Location: Lebanon
Noninvasive bladder cancer diagnostics via machine learning analysis of nanoscale surface images of epithelial cells extracted from voided urine samples
Location: Lebanon
Patient Characteristics and Outcomes in Lymphoma with Pre-existing Autoimmune Diseases
Location: Lebanon
S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B
Location: Lebanon
S1925:Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymph
Location: Lebanon
TURBT post-operative discomfort
Location: Lebanon
Targeted Spatial Transcriptomics in Carcinoma
Location: Lebanon
Thyroid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Chart Review Study
Location: Lebanon
Thyroid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Waiting Room Survey Study
Location: Lebanon
Tumor Tissue Molecular Map Bank
Location: Lebanon
Understanding Interdisciplinary Decision-Making Support for Hospitalized Palliative Care Patients
Location: Lebanon
Usage of Rectal Cancer Clinical Practice Guidelines Among Colorectal Surgeons
Location: Lebanon
Utilizing digital imaging and artificial intelligence to count hematopoietic cells of the bone marrow.
Location: Lebanon
W17171: Shared Care: Patient-Centered Management after Hematopoietic Cell Transplantation
Location: Lebanon
Anus
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
Anus,Bones and Joints,Brain and Nervous System,Breast,Cervix,Colon,Corpus Uteri,Esophagus,Eye and Orbit,Hodgkin Lymphoma,Ill-Defined Sites,Kaposi's Sarcoma,Kidney,Larynx,Leukemia - other,Lip - Oral Cavity and Pharynx,Liver,Lung,Lymphoid Leukemia,Melanoma - Skin,Multiple Myeloma,Mycosis Fungoides,Myeloid and Monocytic Leukemia,Non-Hodgkin's Lymphoma,Other Digestive Organ,Other Endocrine System,Other Female Genital,Other Hematopoietic,Other Male Genital,Other Respiratory and Intrathoracic Organs,Other Skin,Other Urinary,Ovary,Pancreas,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid,Unknown Sites,Urinary Bladder
Clinical study to quantitate radiation dose using Cherenkov Imaging and Dose Dots
Location: Lebanon
Anus
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Bones and Joints
21WAS199: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Location: Lebanon
Bones and Joints,Brain and Nervous System,Esophagus,Eye and Orbit,Ill-Defined Sites,Larynx,Lip - Oral Cavity and Pharynx,Other Digestive Organ,Other Endocrine System,Other Respiratory and Intrathoracic Organs,Other Skin,Soft Tissue,Thyroid,Unknown Sites
Characterizing In Vivo Oral Lesion Impedances
Location: Lebanon
Bones and Joints
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Brain and Nervous System
21EVA033: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients Wit
Location: Lebanon
22ROS404: Evaluation of virus-specific T cells in neurologic tissues from routine surgery
Location: Lebanon
D12160: Evaluating the Expression Levels of MicroRNA-10b in Patients with Gliomas
Location: Lebanon
D20056: Clinical Investigation to Evaluate the CONVIVO System for Discrimination of Normal From Abnormal Tissue During Brain Tumor Resection
Location: Lebanon
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation with Preoperative MR, PpIX Fluorescence and Histology
Location: Lebanon
N0577: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (CODEL)
Location: Lebanon
NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Location: Lebanon
NRG-BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Location: Lebanon
Neuropsychology and Neuroimaging in NeuroOncology
Location: Lebanon
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Umbrella Long-Term Follow Up Protocol
Location: Lebanon
Brain and Nervous System,Leukemia - other
Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel Wafer (Carmustine Implant) Used in Usual Medical Practice
Location: Lebanon
Breast
22CHA436: Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine vs. placebo in patients wit
Location: Lebanon
22CHA800: Genetically-Informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: A Phase II Umbrella Study (GERTRUDE)
Location: Lebanon
22SCH740: Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer (ESTHER)
Location: Lebanon
22VAH835: A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer whose Disease Progressed After Prior Endocrine Based Treated for A
Location: Lebanon
A Pilot Study to validate the combined Automated Whole Breast Ultrasound (ABUS) and Electrical Impedance Tomography (EIT) system in breast-biopsy subjects
Location: Lebanon
A Randomized Two-Arm Proof of Concept Study Testing a Novel Approach to Exercise Promotion Based on Affect-regulation
Location: Lebanon
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tuca
Location: Lebanon
CCTG MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
Increasing physical activity among breast cancer survivors: Use of the ORBIT Model to refine and test a novel approach to exercise promotion based on affect-regulation
Location: Lebanon
Increasing physical activity among breast cancer survivors: Use of the ORBIT Model to refine and test a novel approach to exercise promotion based on affect-regulation
Location: Lebanon
NRG-BR007: A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score [less than or equal to] 18 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
Location: Lebanon
Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Cervix
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Colon
21DRA090: A Phase 1a/1b Study of LY3537982 Administered to Patients with KRAS G12C-Mutant Advanced Solid Tumors
Location: Lebanon
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A022101 : A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR), (NCT TBD)
Location: Lebanon
A022104 - The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Location: Lebanon
Checkpoint Immunotherapy for Tumors Common in Fanconi Anemia
Location: Lebanon
Colonoscopy versus Stool-based Testing for Older Adults with a History of Colon Polyps
Location: Lebanon
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-GI008 : Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Location: Lebanon, St. Johnsbury, VT
Colon,Rectum
New Hampshire Colonoscopy Registry
Location: Lebanon
Colon,Pancreas,Rectum
Plasmonic Nanoantenna Array in Liquid for Early Cancer Biomarker Detection
Location: Lebanon
Colon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Corpus Uteri
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Esophagus
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Eye and Orbit
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Hodgkin Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Location: Lebanon, St. Johnsbury, VT
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Location: Lebanon
Umbrella Long-Term Follow Up Protocol
Location: Lebanon
Kaposi's Sarcoma
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Kidney
Renal Tumors Classification, Biology and Banking Study
Location: Lebanon
S1931 Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Larynx
22DRA472:A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Location: Lebanon
NRG-HN009 : Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Leukemia - other
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Location: Lebanon
AALL1731 - A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Location: Lebanon
APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Location: Lebanon
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
SNF20162 - Protocol for Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens from Children and Young Adults with Hematologic Malignancy
Location: Lebanon
The Impact of Lymphodepletion on Myeloid-Derived Suppressor Cells and Other Immune Modulators in Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy: A Clinical Pilot Study.
Location: Lebanon
Umbrella Long-Term Follow Up Protocol
Location: Lebanon
Lip - Oral Cavity and Pharynx
22DRA472:A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Location: Lebanon
Intraoperative Stereo Imaging of TORS Specimens
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Liver
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Lung
21DRA090: A Phase 1a/1b Study of LY3537982 Administered to Patients with KRAS G12C-Mutant Advanced Solid Tumors
Location: Lebanon
22DRA432:Randomized,Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lu
Location: Lebanon
22DRA472:A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
Location: Lebanon
22DRA773: A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Location: Lebanon
22RUS799: A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS_SCLC)
Location: Lebanon
A211901:Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
Location: Lebanon, St. Johnsbury, VT
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Location: Lebanon
D19052: Understanding Barriers and Facilitators for Lung Cancer Screening in High-Risk Populations
Location: Lebanon
D20034: REGULATORY T-CELL CLONALITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Location: Lebanon
F20074 - NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients with Resectable Stages IB-III Non-Small Cell Lung Cancer
Location: Lebanon
H19095 - A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II lymph-node negative Non-small Cell Lung Cance
Location: Lebanon
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC:RAPTOR trial
Location: Lebanon, St. Johnsbury, VT
NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy followed by Concurrent Mediastinal Chemoradiation for locally Advanced Non-Small Cell Lung Cancer
Location: Lebanon, St. Johnsbury, VT
S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-squamous Non-small Cell Lung Cancer
Location: Lebanon
S2302: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cel
Location: Lebanon, St. Johnsbury, VT
Lymphoid Leukemia
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
The Impact of Lymphodepletion on Myeloid-Derived Suppressor Cells and Other Immune Modulators in Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy: A Clinical Pilot Study.
Location: Lebanon
Melanoma - Skin
D16002: Identification and characterization of skin-resident memory T cells in patients with melanoma-associated vitiligo
Location: Lebanon
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Multiple Myeloma
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
The Impact of Lymphodepletion on Myeloid-Derived Suppressor Cells and Other Immune Modulators in Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy: A Clinical Pilot Study.
Location: Lebanon
Mycosis Fungoides
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
Myeloid and Monocytic Leukemia
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Checkpoint Immunotherapy for Tumors Common in Fanconi Anemia
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
Non-Hodgkin's Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Location: Lebanon, St. Johnsbury, VT
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Location: Lebanon
The Impact of Lymphodepletion on Myeloid-Derived Suppressor Cells and Other Immune Modulators in Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy: A Clinical Pilot Study.
Location: Lebanon
Other Digestive Organ
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Endocrine System
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Umbrella Long-Term Follow Up Protocol
Location: Lebanon
Other Female Genital
22LAN833: A single-arm, open-arm, multicenter Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory mantle cell lymphoma
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Hematopoietic
B0943: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-2002-0063)
Location: Lebanon
Protocol For A Research Sample Repository For Allogeneic Hematopoietic Stem Cell Transplantation And Marrow Toxic Injuries (NMDP #IRB-1991-0002)
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Male Genital
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Respiratory and Intrathoracic Organs
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Skin
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Urinary
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Ovary
22LAN833: A single-arm, open-arm, multicenter Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory mantle cell lymphoma
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Pancreas
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A022001 : Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Location: Lebanon
EA2192 : A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Location: Lebanon, St. Johnsbury, VT
Pancreas Cancer Direct Xenograft Program at Dartmouth-Hitchcock Medical Center
Location: Lebanon
S2001 : Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Location: Lebanon, St. Johnsbury, VT
Prostate
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
Microendoscopic Electrical Impedance Sensing for Real-time Intraoperative Surgical Margin Assessment
Location: Lebanon
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Location: Lebanon, St. Johnsbury, VT
NRG-GU010 Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Location: Lebanon, St. Johnsbury, VT
NRG-GU011 : A Phase II Double-Blind, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NEO PROMETHEAN)
Location: Lebanon, St. Johnsbury, VT
S1802 Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Rectum
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Small Intestine
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Soft Tissue
EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Stomach
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Thyroid
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Unknown Sites
Evaluating the measurement characteristics of the consideRATE questions, a measure of serious illness experience, in a National Cancer Institute Designated Comprehensive Cancer Center
Location: Lebanon
Umbrella Long-Term Follow Up Protocol
Location: Lebanon
Urinary Bladder
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
Phase II Trial Of Intravesical Gemcitabine And Mk-3475 (Pembrolizumab) In The Treatment Of Patients With Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
